SMARCB1

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 · Q12824 · SMARCB1 on Sugi Atlas →

0 patent compounds predicted against SMARCB1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SMARCB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) PHASE3RECRUITING
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer. PHASE2NOT_YET_RECRUITING
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) PHASE2COMPLETED
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma PHASE2RECRUITING
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC PHASE2NOT_YET_RECRUITING
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma PHASE2COMPLETED
Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma PHASE2NOT_YET_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer PHASE2RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer PHASE2ACTIVE_NOT_RECRUITING
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy PHASE2COMPLETED
A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. PHASE2NOT_YET_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types PHASE2COMPLETED
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma PHASE1/PHASE2WITHDRAWN
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation PHASE1COMPLETED
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer PHASE1RECRUITING
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Implementation of FEES in Spinal Muscle Atrophy nanCOMPLETED
Newborn Screening for Spinal Muscular Atrophy nanCOMPLETED
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC nanNOT_YET_RECRUITING
Motor Development and Orthoses in Spinal Muscular Atrophy (SMA) nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Palliative Care in Spinal Muscular Atrophy (SMA) 1 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SMARCB1 binder may also engage these)

ProteinNameSimilarity
Q5U379 1.000 Q5U379 →
Q5BIN2 1.000 Q5BIN2 →
Q9Z0H3 1.000 Q9Z0H3 →
Q5ZK40 1.000 Q5ZK40 →
O42467 1.000 O42467 →
Q6DFM1 1.000 Q6DFM1 →
Q6GQ82 0.998 Q6GQ82 →
Q95RG8 0.991 Q95RG8 →
Q9W3D3 0.990 Q9W3D3 →
Q7Z401 0.990 Q7Z401 →
KDM5B Lysine-specific demethylase 5B 0.989 landscape →
O43150 0.989 O43150 →
G5EDY0 0.989 G5EDY0 →
Q61T02 0.989 Q61T02 →
Q8IP99 0.989 Q8IP99 →
I2HAA0 0.989 I2HAA0 →
Q6CUA5 0.988 Q6CUA5 →
B5E0H4 0.988 B5E0H4 →
DHX29 ATP-dependent RNA helicase DHX29 0.988 landscape →
Q19546 0.988 Q19546 →
Q21037 0.988 Q21037 →
O60152 0.988 O60152 →
G5EFD2 0.988 G5EFD2 →
Q9USM3 0.987 Q9USM3 →
Q5XI06 0.987 Q5XI06 →
SEPTIN8 Septin-8 0.987 landscape →
Q03615 0.987 Q03615 →
Q8N3C0 0.987 Q8N3C0 →
Q94545 0.987 Q94545 →
A0JMA8 0.987 A0JMA8 →